HIV Prevention Trials Network (HPTN) Announces Initiation of HPTN 084: First Large-Scale Study in Women of a Long-Acting Injectable to Prevent HIV
Long-Acting Injectable Cabotegravir for PrEP Well Tolerated in HPTN 077: Results Support Dosing Regimens in HPTN 083 and HPTN 084
Financial Incentives Improve Viral Suppression Among People Living With HIV: Findings from the HPTN 065 Study